基于IgA肾病发病机制的靶向治疗选择
本文综述IgA肾病的发病机制及治疗进展,指出当前标准治疗仍以支持治疗为主,随着对分子机制的认识加深及替代终点被接受,多种靶向新型药物临床试验涌现,有望实现针对不同病理环节的多靶点治疗策略。
要点
- IgA肾病是全球原发性肾小球疾病的首位病因,常进展至慢性肾脏病和肾衰竭。
- 发病机制涉及循环IgA免疫复合物形成及低糖基化IgA1在系膜区沉积。
- 当前标准治疗仍以生活方式调整和阻断肾素-血管紧张素-醛固酮系统为主。
核心结论
- 随着对IgA肾病分子机制的进一步阐明及替代终点被接受加速了药物审批流程,多种靶向IgA肾病的新型研究药物试验已经涌现。
- 作者希望实现全面的多靶点治疗策略:一方面针对持续性肾单位丢失的后果,另一方面抑制肾小球炎症、拮抗肾小球及肾小管间质区域的促纤维化信号通路并减少致病性IgA分子的合成。
研究设计与样本
- 本文为综述,总结IgA肾病治疗策略的最新进展与更新,并强调可能为未来研究提供希望的重要发现。
主要发现
- IgA肾病发病机制极为复杂,涉及循环IgA免疫复合物形成,这些复合物具有独特的化学和生物学特征,促进其在系膜细胞沉积及低糖基化IgA1在系膜细胞中的反应性蓄积,最终导致肾小球硬化和肾间质纤维化的组织损伤。
- 尽管IgA肾病已被广泛认为是一个独立的疾病实体,但针对该病的特异性治疗直到最近才出现。
- 当代标准治疗方案仍以综合支持治疗为中心,包括生活方式调整和靶向阻断肾素-血管紧张素-醛固酮系统。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunoglobulin A nephropathy (IgAN) remains the leading cause of primary glomerular disease globally. The disease often results in progressive chronic kidney disease and eventual kidney failure, and has a poor prognosis, significantly increasing the global healthcare burden. The pathogenesis of IgAN is extremely intricate, involving the formation of circulating IgA immune complexes. These immune complexes have unique chemical and biological characteristics that facilitate their deposition in mesangial cells and the reactive accumulation of underglycosylated IgA1 in mesangial cells, ultimately leading to tissue damage in glomerular sclerosis and renal interstitial fibrosis. Although IgAN has been widely recognized as a separate disease entity, specific treatments for the disease have not been available until recently. Contemporary standard-of-care regimens remain centred on comprehensive supportive management, encompassing lifestyle modifications and targeted blockade of the renin-angiotensin-aldosterone system. In recent years, however, as further elucidating the molecular mechanisms underlying the pathogenesis of IgAN and acceptance of surrogate endpoints has accelerated the drug approval process, a number of novel investigational drug trials targeting IgAN have emerged. With the development of these drugs, we hope to achieve a comprehensive multipronged treatment strategy: on the one hand, to target the consequences of persistent nephron loss, and on the other hand, to suppress glomerular inflammation, antagonize pro-fibrotic signalling pathways within glomerular and tubulointerstitial compartments and curtail the synthesis of pathogenic IgA molecules. This review summarizes recent advances and updates in IgAN treatment strategies and highlights important findings that may provide hope for future research.
引用
- Bo S, Sun A, Yang W, et al. Targeted therapeutic options based on the pathogenesis of IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 40833631. doi:10.1093/ndt/gfaf167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。